MN2 Stock Overview
Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mentice AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.77 |
| 52 Week High | SEK 5.30 |
| 52 Week Low | SEK 1.75 |
| Beta | 1 |
| 11 Month Change | -33.46% |
| 3 Month Change | -25.94% |
| 1 Year Change | -51.90% |
| 33 Year Change | -80.89% |
| 5 Year Change | -75.24% |
| Change since IPO | -71.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| MN2 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -0.1% | -0.02% |
| 1Y | -51.9% | -32.5% | 8.2% |
Return vs Industry: MN2 underperformed the German Healthcare Services industry which returned -33% over the past year.
Return vs Market: MN2 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| MN2 volatility | |
|---|---|
| MN2 Average Weekly Movement | 6.6% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MN2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MN2's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 133 | Göran Malmberg | www.mentice.com |
Mentice AB (publ) provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. The company operates through three segments: Systems, Software Licenses and Service. It offers software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced, essential, and intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.
Mentice AB (publ) Fundamentals Summary
| MN2 fundamental statistics | |
|---|---|
| Market cap | €48.69m |
| Earnings (TTM) | -€2.02m |
| Revenue (TTM) | €24.01m |
2.0x
P/S Ratio-24.1x
P/E RatioIs MN2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MN2 income statement (TTM) | |
|---|---|
| Revenue | SEK 276.06m |
| Cost of Revenue | SEK 32.73m |
| Gross Profit | SEK 243.33m |
| Other Expenses | SEK 266.61m |
| Earnings | -SEK 23.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 88.15% |
| Net Profit Margin | -8.43% |
| Debt/Equity Ratio | 0% |
How did MN2 perform over the long term?
See historical performance and comparison